文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

海马回避全脑放疗脑转移患者治疗前海马体积与神经认知功能的关联:NRG Oncology/RTOG 0933 二次分析

Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933.
PubMed 文献 · Adv Radiat Oncol · 2021-12-11

该研究为NRG Oncology/RTOG 0933的二次分析,评估42例接受海马回避全脑放疗的脑转移患者基线海马体积与神经认知功能的关系。结果显示校正后海马体积增大与基线及4个月时HVLT-R总回忆和延迟回忆评分较高相关,但与神经认知功能变化无关。

要点

  • 校正后海马体积增大与基线及4个月HVLT-R总回忆和延迟回忆评分较高相关。
  • 海马体积与基线至4个月神经认知功能变化无显著关联。
  • 33.3%患者(14例)按主要终点出现神经认知功能恶化,恶化者海马体积数值上较低但无显著差异。

核心结论

  • 在接受海马回避全脑放疗的脑转移患者中,较大的海马体积与基线及4个月时HVLT-R总回忆和延迟回忆评分较高呈正相关,但与神经认知功能变化无关。

研究设计与样本

  • NRG Oncology/RTOG 0933的二次分析,共42例可评估患者。
  • 海马体积和全脑体积从放疗计划中计算。
  • 采用Pearson相关分析海马体积与基线及4个月神经认知功能评分的关联。
  • 神经认知功能恶化按RTOG 0933主要终点定义(4个月HVLT-R延迟回忆平均相对下降)。
  • 采用Wilcoxon检验比较神经认知功能恶化与未恶化患者。

主要发现

  • 中位年龄56.5岁(范围28-83岁),81%为递归分区分析II类。
  • 中位总海马体积5.4 cm3(范围1.9-7.4 cm3),右侧2.8 cm3(范围0.9-4.0 cm3),左侧2.7 cm3(范围1.0-3.7 cm3)。
  • 中位全脑体积1343 cm3(范围1120.5-1738.8 cm3)。
  • 所有校正后海马体积指标增大与基线HVLT-R总回忆和延迟回忆评分较高相关(ρ范围0.35-0.40;P值范围.009-.024),与4个月总回忆和延迟回忆评分较高相关(ρ范围0.29-0.40;P值范围.009-.04),但右侧海马体积与4个月延迟回忆评分除外(ρ=0.29;P=.059)。
  • 海马体积与基线至4个月神经认知功能变化无显著关联;14例(33.3%)按主要终点出现神经认知功能恶化;恶化与未恶化患者间海马体积无显著差异,但恶化者海马体积在所有情况下数值上较低。

关键数值与推荐

  • 神经认知功能恶化按RTOG 0933主要终点定义:4个月HVLT-R延迟回忆平均相对下降。
  • 校正后海马体积增大与基线HVLT-R总回忆和延迟回忆评分较高相关(ρ范围0.35-0.40;P值范围.009-.024)。
  • 校正后海马体积增大与4个月HVLT-R总回忆和延迟回忆评分较高相关(ρ范围0.29-0.40;P值范围.009-.04),但右侧海马体积与4个月延迟回忆评分除外(ρ=0.29;P=.059)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hippocampal volume (HV) is an established predicting factor for neurocognitive function (NCF) in neurodegenerative disease. Whether the same phenomenon exists with hippocampal-avoidant whole brain radiation therapy is not known; therefore, we assessed the association of baseline HV with NCF among patients enrolled on RTOG 0933. METHODS AND MATERIALS: Hippocampal volume and total brain volume were calculated from the radiation therapy plan. Hippocampal volume was correlated with baseline and 4-month NCF scores (Hopkins Verbal Learning Test-Revised [HVLT-R] Total Recall [TR], Immediate Recognition, and Delayed Recall [DR]) using Pearson correlation. Deterioration in NCF was defined per the primary endpoint of RTOG 0933(mean 4-month relative decline in HVLT-R DR). Comparisons between patients with deteriorated and nondeteriorated NCF were made using the Wilcoxon test. RESULTS: Forty-two patients were evaluable. The median age was 56.5 years (range, 28-83 years), and 81% had a class II recursive partitioning analysis. The median total, right, and left HVs were 5.4 cm3 (range, 1.9-7.4 cm3), 2.8 cm3 (range, 0.9-4.0 cm3), and 2.7 cm3 (range, 1.0-3.7 cm3), respectively. The median total brain volume was 1343 cm3 (range, 1120.5-1738.8 cm3). For all measures of corrected HV, increasing HV was associated with higher baseline HVLT-R TR and DR scores (ρ: range, 0.35-0.40; P-value range, .009-.024) and 4-month TR and DR scores (ρ: range, 0.29-0.40; P-value range, .009-.04), with the exception of right HV and 4-month DR scores (ρ: 0.29; P = .059). There was no significant association between HV and NCF change between baseline and 4 months. Fourteen patients (33.3%) developed NCF deterioration per the primary endpoint of RTOG 0933. There was no significant difference in HV between patients with deteriorated and nondeteriorated NCF, although in all instances, patients with deteriorated NCF had numerically lower HV. CONCLUSIONS: Larger HV was positively associated with improved performance on baseline and 4-month HVLT-R TR and DR scores in patients with brain metastases undergoing hippocampal-avoidant whole brain radiation therapy but was not associated with a change in NCF.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Abraham CD, Pugh SL, Bovi JA, et al. Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933. Adv Radiat Oncol. 2021. PMID: 36420209. doi:10.1016/j.adro.2021.100859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。